Articles Published in 2012

Alnylam, Genzyme to develop and commercialize RNAi therapeutics in Asia

Monday, October 22, 2012 12:01 PM

Alnylam Pharmaceuticals, a biopharmaceutical company based in Cambridge, Mass., and Genzyme, a Sanofi company, have formed an exclusive alliance to develop and commercialize RNAi therapeutics targeting transthyretin (TTR) for the treatment of transthyretin-mediated amyloidosis (ATTR) in Japan and other Asia-Pacific countries.

More... »

Catalent Pharma launches Catalent Applied Drug Delivery Institute

Monday, October 22, 2012 11:38 AM

Catalent Pharma Solutions, a developer of solutions and advanced drug delivery technologies, has launched its Catalent Applied Drug Delivery Institute.

More... »

WuXi AppTec opens first cGMP biologics facility in China

Monday, October 22, 2012 11:11 AM

WuXi AppTec, a pharmaceutical, biotechnology and medical device R&D outsourcing company, has opened a cGMP biologics facility in China.

More... »

Charles River Labs, AstraZeneca enter strategic partnership

Monday, October 22, 2012 10:43 AM

AstraZeneca, a global biopharmaceutical company, has selected Charles River Laboratories International, a global provider of research products and services, as its preferred strategic partner for outsourced regulated safety assessment and development DMPK (drug metabolism and pharmacokinetics).

More... »

Venture capital investments decline in dollars and deal volume in Q3 2012

Friday, October 19, 2012 03:26 PM

Venture capitalists invested $6.5 billion in 890 deals in the third quarter of 2012, according to the MoneyTree Report from PricewaterhouseCoopers (PwC) and the National Venture Capital Association (NVCA), based on data provided by Thomson Reuters.

More... »

Resverlogix initiates phase II trial of RVX-208 in pre-diabetes

Friday, October 19, 2012 03:20 PM

Resverlogix, a Canadian clinical stage cardiovascular company, has initiated an exploratory phase II clinical trial in patients with pre-diabetes mellitus to examine the effects of RVX-208 and ApoA-I production on glucose metabolism.

More... »

Former i3 CEO Bilawsky tapped to lead Precision Health Economics

Friday, October 19, 2012 02:55 PM

Health economics partnership Precision Health Economics (PHE) has named Glenn Bilawsky as its CEO. The healthcare consultancy, known for its exceptional, highly decorated and connected team has experienced rapid growth and is looking to Bilawsky to underpin its success with a strategy and business platform that will ensure stability while accelerating expansion of the business.

More... »

Omeros adds two new vice presidents to management team

Friday, October 19, 2012 02:21 PM

Omeros, a Seattle, Wash.-based clinical-stage biopharmaceutical company targeting inflammation, coagulopathies and disorders of the central nervous system, has appointed two new vice presidents: Cathy Melfi, Ph.D. as vice president, regulatory affairs and quality systems, and Albert Yu, M.D., as vice president, clinical development.

More... »

Steris acquires businesses, expands healthcare service business

Friday, October 19, 2012 01:42 PM

Steris, an infection prevention, decontamination, surgical and critical care company based in Mentor, Ohio, purchased two privately-owned businesses: Spectrum Surgical Instruments of Stow, Ohio, and Total Repair Express (TRE) of Hillsborough, N.J.—both providers of surgical instrument repair services and instrument care products to hospitals and surgery centers in the U.S.

More... »

Neurovance closes $7M series A1 round for ADHD drug

Friday, October 19, 2012 12:09 PM

Neurovance, has closed a $7 million series A1 round led by existing investor Novartis Venture Fund to further advance development of EB-1020 for adult attention deficit hyperactivity disorder (ADHD).

More... »